The Next Frontier in Health Disparities—A Closer Look at Exploring Sex Differences in Glioma Data and Omics Analysis, from Bench to Bedside and Back
Open Access
- 30 August 2022
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 12 (9) , 1203
Abstract
Sex differences are increasingly being explored and reported in oncology, and glioma is no exception. As potentially meaningful sex differences are uncovered, existing gender-derived disparities mirror data generated in retrospective and prospective trials, real-world large-scale data sets, and bench work involving animals and cell lines. The resulting disparities at the data level are wide-ranging, potentially resulting in both adverse outcomes and failure to identify and exploit therapeutic benefits. We set out to analyze the literature on women’s data disparities in glioma by exploring the origins of data in this area to understand the representation of women in study samples and omics analyses. Given the current emphasis on inclusive study design and research, we wanted to explore if sex bias continues to exist in present-day data sets and how sex differences in data may impact conclusions derived from large-scale data sets, omics, biospecimen analysis, novel interventions, and standard of care management.Keywords
Funding Information
- NCI NIH intramural program (ZID BC 010990)
This publication has 75 references indexed in Scilit:
- Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide TreatmentAmerican Journal of Clinical Oncology, 2015
- U‐251 revisited: genetic drift and phenotypic consequences of long‐term cultures of glioblastoma cellsCancer Medicine, 2014
- Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade gliomaNeuro-Oncology, 2014
- Do you know the sex of your cells?American Journal of Physiology-Cell Physiology, 2014
- Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylationNeuro-Oncology, 2013
- Phase 2 study of dose-intense temozolomide in recurrent glioblastomaNeuro-Oncology, 2013
- A phase II trial of oral gimatecan for recurrent glioblastomaJournal of Neuro-Oncology, 2012
- MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCRJournal of Translational Medicine, 2012
- PARP-1 protein expression in glioblastoma multiformeEuropean Journal of Histochemistry, 2012
- Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastomaNeuro-Oncology, 2011